New Vaccine Post-Introduction Evaluation - libdoc.who.int - World ...

––
––
––
how well the catch-up campaign worked (if one was used);
in the case of pentavalent introduction, whether the policy on what to
do with excess diphtheria-tetanus-pertussis (DTP) vaccine following the
introduction was adhered to;
in the case of pentavalent, how well the national guidelines for transitioning
those children who had already begun their vaccination with DTP was
adhered to.
If there is no introduction plan in place, the key milestones listed above can still be
evaluated by documenting what preparations were carried out.
Budgeting should be part of the planning process. For GAVI-eligible countries, GAVI
provides time-limited support for new and underutilized vaccines against a co-financing
contribution from the country. At the end of the co-financing period, the country is
expected to take on the full cost of the vaccine. The sustainability of the funding should
be determined by the evaluator responsible for the evaluation at national level;
•
•
to determine whether a budget line exists at the central level for vaccines, including
the new vaccines (for GAVI- and non-GAVI-eligible countries);
to determine whether there are plans for increasing co-funding over time (in
GAVI-eligible countries).
2.2 Coverage, drop-out, recording and reporting
A new vaccine should be introduced according to WHO’s or the manufacturer’s
recommended schedule. Table 5 outlines the recommended schedules for Hib,
pneumococcal and rotavirus vaccines. Schedules for other vaccines can be obtained
from the WHO at http://www.who.int/immunization/policy/immunization_tables/en/
index.html.
Table 5: Immunization schedule of selected new and underutilized vaccines
Vaccine
Haemophilus
influenzae type b
Pneumococcal
conjugate (PCV)
Rotavirus
Doses in
primary
series
Interval between doses
Age at 1st dose 1st to 2nd 2nd to 3rd Booster dose
3 6 weeks (min.)
with DTP-1, 24
months (max.)
3 6 weeks (min.)
with DTP-1
• Rotarix®
2 6 weeks (min.),
12 weeks (max.)
• RotaTeq®
3 6 weeks (min.),
12 weeks (max.)
4 weeks (min.) with
DTP-2
4 weeks (min.) with
DTP-2
4 weeks (min.) and
no later than 24
weeks of age
4 weeks (min.) with
DTP-3
4 weeks (min.) with
DTP-3
Not applicable
4 weeks (min.) 4 weeks (min.) and
no later than 32
weeks of age
No WHO
recommendation
No WHO
recommendation
No booster dose
WHO/IVB/10.03
9